Damien Fayolle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Damien Fayolle has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Annemarie Hübers
Department of Clinical Neurosciences, Division of Neurology, Geneva University Hospitals, 1205 Geneva, Switzerland
1 shared publication - Eglė Sukockienė
Department of Clinical Neurosciences, Division of Neurology, Geneva University Hospitals, 1205 Geneva, Switzerland
1 shared publication - Gautier Breville
Department of Neurology (A.R., G.B., R.L., A.B.-O.), Perelman School of Medicine, University of Pennsylvania, Philadelphia
1 shared publication - Marjolaine Uginet
Department of Clinical Neurosciences, Division of Neurology, Geneva University Hospitals, 1205 Geneva, Switzerland
1 shared publication - Umberto Nencha
Division of Geriatric Psychiatry, University Hospitals of Geneva (HUG), 1226 Thônex, Switzerland
1 shared publication
Latest Publications
- Open Access
Case Series of Acute Peripheral Neuropathies in Individuals Who Received COVID-19 Vaccination
Background and Objectives: Vaccination has been critical to managing the COVID-19 pandemic. Autoimmunity of the nervous system, especially among a select set of high-risk groups, can be triggered or enhanced by the contents of vaccines. Here, we report a case series of acute peripheral neuropathies following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on 11 patients (range: 30–90 years old) who presented at our center between January 2021 and February 2022. Methods: We obtained the patients’ history and performed clinical neurological examination and electromyoneurography on all subjects. If necessary, magnetic resonance imaging and laboratory testing, including cerebrospinal fluid analysis and specific antibody testing, were performed. Results: Patients presented with peripheral neuropathies of acute onset between 1 and 40 days after vaccination with different types of COVID-19 vaccines. Most cases (9/11) resolved with a rapid, complete or partial recovery. Conclusions: We found acute peripheral neuropathies in a set of individuals after they received vaccines against SARS-CoV-2. Albeit our observation shows that during extensive vaccination programs, negative side effects on the peripheral nervous system might occur, most of them showed benign clinical evolution. Thus, potential side effects should not hinder the prescription of vaccines. More extensive studies are needed to elucidate populations at risk of developing peripheral neuropathies and mechanisms of autoimmune response in the nervous system.
Open AccessCase Series of Acute Peripheral Neuropathies in Individuals Who Received COVID-19 Vaccination
Background and Objectives: Vaccination has been critical to managing the COVID-19 pandemic. Autoimmunity of the nervous system, especially among a select set of high-risk groups, can be triggered or enhanced by the contents of vaccines. Here, we report a case series of acute peripheral neuropathies following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on 11 patients (range: 30–90 years old) who presented at our center between January 2021 and February 2022. Methods: We obtained the patients’ history and performed clinical neurological examination and electromyoneurography on all subjects. If necessary, magnetic resonance imaging and laboratory testing, including cerebrospinal fluid analysis and specific antibody testing, were performed. Results: Patients presented with peripheral neuropathies of acute onset between 1 and 40 days after vaccination with different types of COVID-19 vaccines. Most cases (9/11) resolved with a rapid, complete or partial recovery. Conclusions: We found acute peripheral neuropathies in a set of individuals after they received vaccines against SARS-CoV-2. Albeit our observation shows that during extensive vaccination programs, negative side effects on the peripheral nervous system might occur, most of them showed benign clinical evolution. Thus, potential side effects should not hinder the prescription of vaccines. More extensive studies are needed to elucidate populations at risk of developing peripheral neuropathies and mechanisms of autoimmune response in the nervous system.